Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Enphase Energy Inc. Stock Slides 5.4%, Underperforms Peers

Enphase Energy Inc. Stock Slides 5.4%, Underperforms Peers

Dow JonesDow Jones2026/09/09 20:33

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Enphase Energy Inc. slid 5.4% to $36.72 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.5% to 7,636.36 and Dow Jones Industrial Average falling 0.8% to 52,380.66.

The stock's fall snapped a three-day winning streak.

Enphase Energy Inc. closed 50.2% short of its 52-week high of $73.74, which the company achieved on May 29th.

The stock underperformed when compared to some of its peers, as Eaton Corp. PLC fell 1.6% to $415.22, TE Connectivity PLC fell 0.2% to $204.68, and Amphenol Corp. Cl A fell 0.51% to $81.34.

Trading volume totaled 5.2 million, compared to the 50-day average of 4.7 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

September 09, 2026 16:33 ET (20:33 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.

智通财经2026/09/14 01:06
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas